Joseph Luinstra, MD
Family Medicine · Newton, KSNPI 1356378236
Payments from drug & device makers
Across 276 payments — averaging $13.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$688
- Novo Nordisk$514
- Pfizer$490
- GSK$303
- Boehringer Ingelheim$288
- Amgen$246
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,794100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 53 | $688 |
| Novo Nordisk | 43 | $514 |
| Pfizer | 39 | $490 |
| GSK | 21 | $303 |
| Boehringer Ingelheim | 19 | $288 |
| Amgen | 17 | $246 |
| Merck | 15 | $220 |
| AstraZeneca | 10 | $194 |
| Sanofi-aventis U.S. LLC | 11 | $160 |
| AbbVie(2 entities) | 7 | $102 |
| Astellas Pharma US Inc | 6 | $81 |
| Johnson & Johnson(2 entities) | 5 | $78 |
| Abbott | 4 | $67 |
| Bayer | 4 | $62 |
| Sunovion Pharmaceuticals Inc. | 5 | $50 |
| Sanofi Pasteur Inc. | 2 | $50 |
| Shire North American Group Inc | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Genentech USA, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Tris Pharma Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$3,808 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 186 | $296,835 |
| XareltoRivaroxaban | 202 | $268,015 |
| TrulicityDulaglutide | 107 | $151,850 |
| OzempicSemaglutide | 98 | $110,609 |
| LinzessLinaclotide | 73 | $87,663 |
| JanuviaSitagliptin Phosphate | 64 | $80,746 |
| MounjaroTirzepatide | 59 | $62,432 |
| EliquisApixaban | 56 | $60,095 |
| InvokanaCanagliflozin | 27 | $34,677 |
| FarxigaDapagliflozin Propanediol | 20 | $27,679 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 13 | $22,280 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $20,861 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $18,740 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $18,205 |
| Bydureon BciseExenatide Microspheres | 18 | $17,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invokana | $78 | $302,693229 claims |
| Boehringer IngelheimJardiance | $288 | $296,835186 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $688 | $214,282166 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $514 | $132,889111 claims |
| AbbVieLinzess | $102 | $87,66373 claims |
| MerckJanuvia | $220 | $80,74664 claims |
| PfizerEliquis | $490 | $60,09556 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $194 | $42,80442 claims |
| GSKAnoro Ellipta, Shingrix | $303 | $20,79158 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $160 | $18,74021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Newton
- Richard GloverNewton$19.6M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
- Robyn HartvicksonNewton$2M
- Terry PolingWichita$24.2M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.